propranolol has been researched along with Bilharziasis in 13 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 9.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| " Forty consecutive patients with bleeding oesophageal varices underwent either injection sclerotherapy only or injection sclerotherapy with an adjuvant fixed daily dose of propranolol (40 mg tds) in a single-blind randomized controlled trial." | 9.11 | Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating the effect of adjuvant propranolol therapy. ( Abdel Baki, M; Dowidar, N; Hafez, A, 2005) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 9.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "Eight Sudanese patients with hepatosplenic schistosomiasis and seven Sudanese controls were administered a single oral dose of long acting (LA), propranolol 160 mg; blood propranolol levels were measured at regular intervals for 12 h using g." | 7.67 | Propranolol disposition in patients with hepatosplenic schistosomiasis. ( Ali, HM; Arbab, BM; Harron, DW; Homeida, MM, 1987) |
| "Propranolol is a non-selective beta-blocker used as secondary prophylaxis for UVB, but no previous studies have addressed carvedilol effects in rebleeding prevention." | 5.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| "To compare the effects of propranolol (PR) to that of PR plus isosorbide-5-mononitrate (ISMN) on variceal pressure in patients with schistosomiasis." | 5.17 | Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. ( Chen, C; Hao, JH; Kong, DR; Li, P; Ma, C; Wang, JG; Wang, M; Xu, JM; Zhang, L, 2013) |
| " Forty consecutive patients with bleeding oesophageal varices underwent either injection sclerotherapy only or injection sclerotherapy with an adjuvant fixed daily dose of propranolol (40 mg tds) in a single-blind randomized controlled trial." | 5.11 | Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating the effect of adjuvant propranolol therapy. ( Abdel Baki, M; Dowidar, N; Hafez, A, 2005) |
| " In the present, double-blind, 24-month, prospective study of patients with endoscopically-proven varices and ultrasonographically-confirmed hepatic fibrosis, the effects of propranolol 160 mg LA and placebo on the incidence of rebleeding and mortality were compared in 82 patients with portal hypertension secondary to schistosomiasis." | 5.07 | Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. ( el Amin, AA; el Tourabi, H; Harron, DW; Homeida, M; Shaheen, M; Woda, SA, 1994) |
| "This study evaluates systemic and splanchnic haemodynamics and the effect of propranolol in 15 patients with presinusoidal portal hypertension (portal vein obstruction, n = 11; schistosomiasis, n = 4)." | 3.67 | Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol. ( Braillon, A; Hadengue, A; Lebrec, D; Moreau, R; Roulot, D; Sayegh, R, 1989) |
| "Eight Sudanese patients with hepatosplenic schistosomiasis and seven Sudanese controls were administered a single oral dose of long acting (LA), propranolol 160 mg; blood propranolol levels were measured at regular intervals for 12 h using g." | 3.67 | Propranolol disposition in patients with hepatosplenic schistosomiasis. ( Ali, HM; Arbab, BM; Harron, DW; Homeida, MM, 1987) |
| "Propranolol is a non-selective beta-blocker used as secondary prophylaxis for UVB, but no previous studies have addressed carvedilol effects in rebleeding prevention." | 1.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| "Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide." | 1.35 | Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. ( Arnér, ES; Austin, CP; Chakrapani, H; Inglese, J; Jadhav, A; Keefer, L; Lea, WA; Leister, W; Luecke, HF; Maloney, DJ; Prast-Nielsen, S; Rai, G; Sayed, AA; Shen, M; Simeonov, A; Thomas, CJ; Williams, DL, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Rai, G | 1 |
| Sayed, AA | 1 |
| Lea, WA | 1 |
| Luecke, HF | 1 |
| Chakrapani, H | 1 |
| Prast-Nielsen, S | 1 |
| Jadhav, A | 1 |
| Leister, W | 1 |
| Shen, M | 1 |
| Inglese, J | 1 |
| Austin, CP | 1 |
| Keefer, L | 1 |
| Arnér, ES | 1 |
| Simeonov, A | 1 |
| Maloney, DJ | 1 |
| Williams, DL | 1 |
| Thomas, CJ | 1 |
| de Abreu, ES | 1 |
| Nardelli, MJ | 1 |
| Lima, AMC | 1 |
| Cardoso, JB | 1 |
| Osório, FMF | 1 |
| Ferrari, TCA | 1 |
| Faria, LC | 1 |
| Couto, CA | 1 |
| Cançado, GGL | 1 |
| Kong, DR | 1 |
| Ma, C | 1 |
| Wang, M | 1 |
| Wang, JG | 1 |
| Chen, C | 1 |
| Zhang, L | 1 |
| Hao, JH | 1 |
| Li, P | 1 |
| Xu, JM | 1 |
| Juraschek, SP | 1 |
| Bankova, L | 1 |
| Falade, O | 1 |
| Chow, G | 1 |
| McKenzie, R | 1 |
| Bhogal, HK | 1 |
| Dowidar, N | 1 |
| Hafez, A | 1 |
| Abdel Baki, M | 1 |
| el Tourabi, H | 1 |
| el Amin, AA | 1 |
| Shaheen, M | 1 |
| Woda, SA | 1 |
| Homeida, M | 1 |
| Harron, DW | 2 |
| Ferraz, AA | 1 |
| Wanderley, GJ | 1 |
| Santos, MA | 1 |
| Mathias, CA | 1 |
| Araújo, JG | 1 |
| Ferraz, EM | 1 |
| Fayez, MA | 1 |
| Aziz, S | 1 |
| el-Gengehy, MT | 1 |
| Othman, A | 1 |
| Blendis, LM | 1 |
| Conn, HO | 1 |
| Braillon, A | 1 |
| Moreau, R | 1 |
| Hadengue, A | 1 |
| Roulot, D | 1 |
| Sayegh, R | 1 |
| Lebrec, D | 1 |
| el-Hawy, A | 1 |
| el Nasr, MS | 1 |
| Hussein, T | 1 |
| el-Sayed, AA | 1 |
| Homeida, MM | 1 |
| Ali, HM | 1 |
| Arbab, BM | 1 |
4 trials available for propranolol and Bilharziasis
| Article | Year |
|---|---|
Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis.
Topics: Adult; China; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Gastrointestinal He | 2013 |
Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating the effect of adjuvant propranolol therapy.
Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Esophageal and Gastric Varices; Female; Humans; Mal | 2005 |
Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis.
Topics: Adult; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hum | 1994 |
Effects of propranolol on human postoperative ileus.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Colon; Electromyography; Female; Gastrointestinal Motility | 2001 |
9 other studies available for propranolol and Bilharziasis
| Article | Year |
|---|---|
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
Topics: Animals; Biological Availability; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentratio | 2009 |
Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Propranol | 2022 |
An uncommon cause of portal hypertension: schistosomiasis.
Topics: Adult; Animals; Anthelmintics; Antihypertensive Agents; Hepatomegaly; Humans; Hypertension, Portal; | 2011 |
Effect of B-blockers on the hepatic blood flow in bilharzial hepatosplenomegaly.
Topics: Adolescent; Adult; Female; Hepatomegaly; Humans; Liver Circulation; Male; Propranolol; Schistosomias | 1975 |
The influence of propanolol on portosystemic shunting.
Topics: Animals; Blood Circulation; Hypertension, Portal; Mice; Mice, Inbred C3H; Portal System; Propranolol | 1991 |
Propranolol-induced reduction in recurrent variceal hemorrhage in schistosomiasis.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Propranolol; Recurrence; Schist | 1990 |
Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. Effect of propranolol.
Topics: Adult; Collateral Circulation; Female; Gastrointestinal Hemorrhage; Heart Rate; Hemodynamics; Hepati | 1989 |
Comparative study between propranolol and sclerotherapy in prophylactic treatment of oesophageal varices and prevention of recurrent bleeding attacks.
Topics: Adult; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Propr | 1987 |
Propranolol disposition in patients with hepatosplenic schistosomiasis.
Topics: Adolescent; Adult; Female; Humans; Liver Diseases, Parasitic; Male; Middle Aged; Propranolol; Schist | 1987 |